Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

10-14 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
23/09/26	€0.6990	-1.27%
22/09/26	€0.7080	+0.85%
21/09/26	€0.7020	+1.15%
18/09/26	€0.6940	+4.83%
17/09/26	€0.6620	+1.85%

Real-time Boerse Muenchen

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Boerse Muenchen 23:43:50 23/09/2026 +03			5-day change	1st Jan Change
0.6990 ^EUR	-1.27%		+8.00%	+19.69%

09-16	Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-16	Theraclion widens its operating loss in the first half

Market Cap	50.08M 57.06M 47.07M 43.04M 80.42M 5.47B 81.02M 565M 219M 2.79B 214M 210M 9.03B	P/E 2024	-2.66x	P/E 2025	-6.33x
Enterprise Value	57.93M 66M 54.46M 49.79M 93.03M 6.32B 93.73M 654M 254M 3.22B 248M 242M 10.45B	EV / Sales 2024	22.5x	EV / Sales 2025	55.4x
Free-Float	31.92%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALTHE	Real-time
Börse Stuttgart	941	Delayed
Boerse Muenchen	941	Real-time
Deutsche Boerse AG	941	Delayed
CBOE		Real-time
CBOE		Real-time

09-16	Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-16	Theraclion widens its operating loss in the first half
07-23	Theraclion SA Reports Consolidated Revenue Results for the First Half Ended June 30, 2026	CI
07-09	Theraclion Announces Board Changes	CI
07-09	Theraclion Appoints New Chairman	MT
06-19	Claude Lenoir appointed interim chairman of Theraclion
06-19	Theraclion Chairman Steps Down; Interim Successor Named	MT
06-18	Theraclion Announces Board Changes	CI
06-08	Theraclion Secures AMA CPT Editorial Panel Approval For New Category III CPT Code For Sonovein	CI
06-05	Theraclion deploys first Sonovein system in China
06-05	Theraclion JV Deploys Sonovein System at Chinese Hospital	MT
06-04	Theraclion Announces First Clinical Deployment Of Sonovein In Hainan, China	CI
06-04	Theraclion Deploys Sonovein System At Boao Super Hospital in Hainan Province	CI

Theraclion Stock Boerse Muenchen

Stocks

941

FR0010120402

Advanced Medical Equipment & Technology

Valuation: Theraclion

Chart: Theraclion

Latest news: Theraclion

Press Releases: Theraclion

News in other languages: Theraclion

Quotes and Performance

Price Extremes

Managers and Directors: Theraclion

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-16	2026 Half-Year Results: Theraclion Prepares for a New Stage in Its Development	BU
07-23	Theraclion Initiates Its Commercial Momentum in the First Half of 2026	BU
07-15	Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL	BU
07-09	Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors	BU
06-18	Theraclion Announces the Evolution of Its Board of Directors	BU

09-16	Theraclion creuse sa perte d'exploitation au 1er semestre
09-16	RÉSULTATS SEMESTRIELS 2026 : THERACLION SE PRÉPARE À UNE NOUVELLE ÉTAPE DE SON DÉVELOPPEMENT
07-23	THERACLION AMORCE SA DYNAMIQUE COMMERCIALE AU PREMIER SEMESTRE 2026
07-15	Theraclion: BILAN DU PREMIER SEMESTRE 2026 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LE CRÉDIT INDUSTRIEL ET COMMERCIAL
07-09	Vincent Gardès prend la présidence du conseil d'administration de Theraclion

1 day	-1.27%
Current month	+5.11%
1 month	-6.68%
3 months	+5.11%
6 months	+41.21%
Current year	+19.69%

1 month	0.7	0.75
Current year	0.44	0.87
1 year	0.44	0.87
3 years	0.14	0.94
5 years	0.14	0.94
10 years	0.14	0.94

Manager	Title	Age	Since
Martin Deterre CEO	Chief Executive Officer	-	24/05/2023
Julie Veisseire DFI	Director of Finance/CFO	-	-
Alexandra Rocher COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Mehdi El Glaoui BRD	Director/Board Member	-	22/06/2021
Cédric Bellanger BRD	Director/Board Member	-	28/01/2022
Lijuan Deng BRD	Director/Board Member	-	29/06/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERACLION	-1.27%	+8.00%	-	-	58.9M
THERMO FISHER SCIENTIFIC, INC.	+1.03%	+2.60%	+41.63%	+32.32%	243B
DANAHER CORPORATION	+0.21%	+6.34%	+16.78%	-10.79%	155B
INTUITIVE SURGICAL, INC.	-0.94%	+4.19%	-11.04%	+38.20%	142B
BOSTON SCIENTIFIC CORPORATION	-0.67%	+1.62%	-54.32%	-16.75%	65.1B
EDWARDS LIFESCIENCES CORPORATION	-2.21%	-2.76%	+16.43%	+24.63%	51.17B
SIEMENS HEALTHINEERS AG	-0.61%	-3.02%	-20.99%	-21.63%	47.67B
AGILENT TECHNOLOGIES, INC.	-1.16%	+7.57%	+31.27%	+48.39%	47.16B
WATERS CORPORATION	-1.21%	+0.46%	+40.56%	+56.35%	41.83B
ILLUMINA, INC.	+3.20%	+11.55%	+157.00%	+92.83%	37.37B
Average	-0.36%	+3.83%	+24.15%	+27.06%	92.36B
Weighted average by Cap.	-0.03%	+4.03%	+19.87%	+22.69%

	2024	2025
Net sales	830K 946K 780K 713K 1.33M 90.61M 1.34M 9.37M 3.63M 46.2M 3.55M 3.47M 150M	652K 743K 613K 560K 1.05M 71.16M 1.05M 7.36M 2.85M 36.28M 2.79M 2.73M 118M
Net income	-5.76M -6.56M -5.41M -4.95M -9.25M -628M -9.31M -65M -25.2M -320M -24.63M -24.09M -1.04B	-5.69M -6.48M -5.35M -4.89M -9.14M -621M -9.21M -64.24M -24.91M -317M -24.35M -23.81M -1.03B
Net Debt	3.41M 3.89M 3.21M 2.93M 5.48M 372M 5.52M 38.51M 14.93M 190M 14.59M 14.27M 615M	7.85M 8.95M 7.38M 6.75M 12.61M 857M 12.7M 88.66M 34.37M 437M 33.6M 32.86M 1.42B